睿知中国疾病研究地图
候选清单0

正在招募IgA 肾病早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of YKST02 in Participants With Primary IgA Nephropathy

ClinicalTrials.gov 上登记的一项IgA 肾病开放试验,由华中科技大学同济医学院附属协和医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07498673,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Women of childbearing potential must have a negative pregnancy test prior to study drug administration and agree to use effective contraception; male participants must agree to use effective contraception

    入选标准第 4 条

  3. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m²

    排除标准第 5 条

  4. Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection

    排除标准第 17 条

    Malignancy within the past 5 years, except adequately treated non-invasive cancers

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07498673,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Diagnosis of primary IgA nephropathy (IgAN)
  2. Proteinuria above a protocol-defined threshold at screening
  3. Receiving stable standard-of-care therapy for IgAN for an adequate duration prior to enrollment, unless contraindicated or not tolerated
  4. Women of childbearing potential must have a negative pregnancy test prior to study drug administration and agree to use effective contraception; male participants must agree to use effective contraception
  5. Able to understand the study procedures and provide written informed consent

排除标准:Exclusion Criteria:

  1. Secondary IgA nephropathy (e.g., associated with liver disease, autoimmune disorders, infections, or other systemic conditions)
  2. Other clinically significant renal diseases unrelated to IgAN (e.g., diabetic nephropathy, lupus nephritis, vasculitis)
  3. Nephrotic syndrome considered unsuitable for study participation
  4. Rapidly progressive glomerulonephritis or rapidly declining renal function
  5. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m²
  6. Immunodeficiency or low immunoglobulin G (IgG) levels below normal
  7. Clinically significant abnormal laboratory findings (e.g., hematologic, hepatic, or coagulation abnormalities)
  8. Requirement for systemic corticosteroids for concomitant conditions
  9. Use of immunosuppressive, targeted, or biologic therapies within a defined period prior to screening or anticipated use during the study
  10. Prior treatment with B-cell-depleting or other targeted biologic therapies within a defined period
  11. History of demyelinating disorders (e.g., multiple sclerosis)
  12. Clinically significant cardiovascular or cerebrovascular disease within 6 months prior to screening
  13. History of organ transplantation or planned transplantation during the study
  14. Current dialysis or anticipated need for dialysis during the study
  15. Major surgery within 4 weeks prior to screening or planned during the study
  16. Active infection requiring systemic therapy, recent serious infection, or chronic/recurrent infections
  17. Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
  18. Active or untreated latent tuberculosis
  19. History of splenectomy
  20. Uncontrolled comorbidities (e.g., poorly controlled hypertension or diabetes)
  21. Malignancy within the past 5 years, except adequately treated non-invasive cancers
  22. Known hypersensitivity to YKST02 or its components
  23. Receipt of another investigational product within 4 weeks or 5 half-lives (whichever is longer) prior to screening
  24. Receipt of live or attenuated vaccines within 4 weeks prior to screening or planned during the study
  25. Any condition that, in the investigator's judgment, would make the participant unsuitable for the study

引自 ClinicalTrials.gov, NCT07498673, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07498673,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07498673